Prescription Drug Areas
While the majority of the therapeutic benefit from PsoriaFilm is due to amplification of percutaneous delivery of corticosteroid, calcipotriol provides some added benefit. The efficacy of calcipotriol in the treatment of psoriasis was first noticed by the observation of patients receiving various forms of vitamin D in an osteoporosis study. Unexpectedly, some patients who also suffered from psoriasis experienced dramatic reductions in lesion counts. Calcipotriol is an analog of Vitamin-D and the delivery of this is covered by our patents. The vitamin D receptor belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kidney, and T cells of the immune system. T cells are known to play a role in psoriasis, and it is thought that the binding of calcipotriol to the VDR modulates the T cells gene transcription of cell differentiation and proliferation related genes in the psoriasis process. Our pipeline product includes film-delivery of calcipotriol as well transdermal, amplified and highly targeted delivery of corticosteroids. This combined approach promises to be uniquely effective in providing relief for psoriasis sufferers without resorting to injectables or dangerous systemic immunosuppressives. It is attractive as a cost-saving measure offering a much less expensive and safer alternative to Anti-TNF- α drugs.
Prescription Products R&D Completed
FDA Stage Estimates
Our prescription drug line falls into a special-case category in the U.S. FDA approval process. This situation allows for an expeditious pathway to approval for many of our products. We expect to find similar treatment as we approach regulatory agencies worldwide, offering them a better, cheaper and safer alternative to current therapy.
PsoriaFilm - Approximately Stage III70%
CortiFilm - Approximately Stage II50%
ScaRx Film - Approximately Stage III65%
Smooth-n-Young - Approximately Stage II60%